Index

Galapagos (Euronext & NASDAQ: GLPG) is a fully integrated biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical and discovery studies in inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib, a JAK1-selective inhibitor for inflammatory indications now available to patients in Europe and Japan under the brand name Jyselica. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, has over 1000 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, Switzerland and the US.